Skip to main content
. 2014 Mar 15;14:192. doi: 10.1186/1471-2407-14-192

Table 2.

Distribution of nuclear β-catenin and E-cadherin relative to different clinicopathological prognostic factors

Prognostic factors
 All patients
 E-cadherin
 P
 Nuclear β-catenin
 P
 
  
 Absence vs. presence
  
 Absence vs. presence
  
 
 N
 %
 N
 %
 N
 %
  
 N
 %
 N
 %
  
  98 100 46 47% 52 53%   74 76% 24 24  
Sex
  
  
  
  
  
  
  
  
  
  
  
  
  Male
 72
 73%
 33
 46%
 39
 54%
 P=0.4
 56
 78%
 16
 22%
 P=0.4
  Female
 26
 27%
 13
 50%
 13
 50%
 18
 69%
 8
 31%
Age
  
  
  
  
  
  
  
  
  
  
  
 P=0.9
  </= 50
 48
 49%
 9
 64%
 36%
 5
 P=0.6
 10
 71%
 4
 29%
  >50
 50
 51%
 37
 44%
 47
 56%
 64
 76%
 20
 24%
Distance to anal margin
  
  
  
  
  
  
  
  
  
  
  
 P=0.7
  </= 5 cm
 84
 86%
 22
 46%
 26
 54%
 P=0.8
 38
 79%
 10
 21%
  >5 cm
 14
 14%
 24
 48%
 26
 52%
 36
 72%
 14
 28%
T stage
  
  
  
  
  
  
  
  
  
  
  
 P=0.4
  T2-3
 82
 83%
 38
 47%
 42
 53%
 P=0.8
 59
 74%
 21
 26%
  T4
 17
 17%
 8
 44%
 10
 56%
 15
 83%
 3
 17%
N stage
  
  
  
  
  
  
  
  
  
  
  
 P=0.2
  N-
 43
 44%
 19
 43%
 25
 57%
 P=0.5
 19
 43%
 25
 57%
  N+
 55
 56%
 27
 50%
 37
 50%
 22
 41%
 32
 59%
TGR*
  
  
  
  
  
  
  
  
  
  
  
 P=0.6
  TGR 1-2
 44
 45%
 18
 41%
 26
 59%
 P=0.2
 32
 73%
 12
 27%
  TGR 3-5
 54
 55%
 28
 52%
 26
 48%
  
 42
 78%
 12
 22%
pN ††
  
  
  
  
  
  
 P=0.8  
  
  
  
 P=0.9
  pN-
 70
 71%
 20
 74%
 7
 26%
 30
 44%
 41
 56%
  pN+ 28 29% 54 76% 17 24% 11 41% 16 59%

*TGR: Tumor grade regression. †† pN: pathological lymphatic metastases.